Press Release: Sanofi teams up with McLaren Racing to accelerate
industrial excellence
Sanofi teams up with McLaren Racing to
accelerate industrial excellence
Paris,
April 26. Sanofi announces today
that it is partnering with McLaren Racing to accelerate
manufacturing efficiency and performance in support of the
company’s ambition to attain world-class standards of manufacturing
excellence. Following a successful pilot in 2021 with McLaren
Racing, both companies have decided to extend their collaboration
across multiple sites in seven countries, covering more than 100
production lines, across all technologies. Learnings from this
partnership will provide insights and develop best practices for
manufacturing that will then be implemented across Sanofi’s global
industrial network .
Paul
HudsonChief Executive Officer“We are thrilled to partner
with McLaren and learn from their winning spirit and culture of
going over and above. I see a lot of commonalities in our shared
values to stretch, with courage and determination, so we can
maximize performance and operational excellence. We want to run our
lines with the speed, precision and efficiency of an F1 racing
team.”
McLaren Racing experts will collaborate with
Sanofi’s Industrial Affairs team to enable continued optimization
of its manufacturing operations, enabling its global network to
better support the supply of its broad portfolio, as well as
enhancing the delivery of its R&D pipeline, with 25 new
launches expected in the next five years to meet patients’ needs
around the world.
With a unique data-driven approach, McLaren
Racing will bring its digital and analytical expertise and skills
to further elevate Sanofi’s performance by helping to better
anticipate and resolve issues before they take place. Modelling
simulation of production line changeovers and operations will be
key areas of McLaren’s Formula 1 experience, as exemplified using
advanced data analytics and expertise used to optimize the famed
pit stops of F1 races.
Zak BrownChief Executive
Officer, McLaren Racing“We are thrilled to be partnering with
Sanofi. It is important that two global companies who share values
work together to maximise performance. We look forward to
continuing to collaborate with Sanofi to make a positive impact not
only in manufacturing but to help Sanofi improve patients'
lives.”
Beyond the technical leadership from F1, the
collaboration will bring a specific focus on the people dimension
of high performance. The partnership will bring a race-like
mindset, emulating the competitive, fast paced environment of F1
racing to help accelerate improvements, learnings and sharing of
best practices individually and collectively across sites,
fostering a “one Sanofi spirit.” This unique opportunity will marry
the best of the two companies with the speed, agility, teamwork,
and constant improvement required to succeed in motor racing, as
well as in healthcare discoveries.
Brendan O’CallaghanExecutive
Vice President for Industrial Affairs, Sanofi“We aspire to
industry-leading capability across our global network of sites, so
we can deliver on our mission to translate the miracles of science
- discovered in our laboratories - into reality for patients. This
program represents a great opportunity to improve our manufacturing
sites' performance with a leading partner like McLaren, who
personifies high performance in a fast-paced, ultra-competitive
environment, leveraging advanced data driven analytics and
precision engineering to gain a winning edge. Accelerating our
performance in this way will help us further expand the reach of
our medicines to even more patients around the world.”
About McLaren RacingMcLaren Racing was founded
by New Zealand racing driver Bruce McLaren in 1963. The team
entered its first Formula 1 race in 1966, since then McLaren has
won 20 Formula 1 world championships, more than 180 Formula 1
grands prix, the Indianapolis 500 three times, and the Le Mans 24
Hours at its first attempt. The team competes in the FIA Formula 1
World Championship with Lando Norris and Daniel Ricciardo, the NTT
INDYCAR Series with Arrow McLaren SP drivers Pato O’Ward and Felix
Rosenqvist, and the Extreme E Championship with Emma Gilmour and
Tanner Foust.McLaren was the first F1 team to be awarded the Carbon
Trust Standard in 2010 and has retained it since on a bi-annual
basis, most recently in February 2021. The team was also the first
in F1 to be given the FIA Sustainability Accreditation Award at a
three-star level in 2013 as part of the FIA Environmental
Certification framework, before becoming a signatory to the UN
Sports for Climate Action Commitment in 2021.
About SanofiWe are an innovative global
healthcare company, driven by one purpose: we chase the miracles of
science to improve people’s lives. Our team, across some 100
countries, is dedicated to transforming the practice of medicine by
working to turn the impossible into the possible. We provide
potentially life-changing treatment options and life-saving vaccine
protection to millions of people globally, while putting
sustainability and social responsibility at the center of our
ambitions. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY
Media RelationsSandrine
Guendoul | + 33 6 25 09 14 25
| sandrine.guendoul@sanofi.comNicolas
Obrist | + 33 6 77 21 27 55
| nicolas.obrist@sanofi.com
Investor RelationsEva
Schaefer-Jansen | + 33 7 86 80 56 39
| eva.schaefer-jansen@sanofi.comFelix
Lauscher | + 1 908 612 7239 |
felix.lauscher@sanofi.com
Sanofi Forward-Looking
StatementsThis press release contains forward-looking
statements as defined in the Private Securities Litigation Reform
Act of 1995, as amended. Forward-looking statements are statements
that are not historical facts. These statements include projections
and estimates and their underlying assumptions, statements
regarding plans, objectives, intentions and expectations with
respect to future financial results, events, operations, services,
product development and potential, and statements regarding future
performance. Forward-looking statements are generally identified by
the words “expects”, “anticipates”, “believes”, “intends”,
“estimates”, “plans” and similar expressions. Although Sanofi’s
management believes that the expectations reflected in such
forward-looking statements are reasonable, investors are cautioned
that forward-looking information and statements are subject to
various risks and uncertainties, many of which are difficult to
predict and generally beyond the control of Sanofi, that could
cause actual results and developments to differ materially from
those expressed in, or implied or projected by, the forward-looking
information and statements. These risks and uncertainties include
among other things, the uncertainties inherent in research and
development, future clinical data and analysis, including post
marketing, decisions by regulatory authorities, such as the FDA or
the EMA, regarding whether and when to approve any drug, device or
biological application that may be filed for any such product
candidates as well as their decisions regarding labelling and other
matters that could affect the availability or commercial potential
of such product candidates, the fact that product candidates if
approved may not be commercially successful, the future approval
and commercial success of therapeutic alternatives, Sanofi’s
ability to benefit from external growth opportunities, to complete
related transactions and/or obtain regulatory clearances, risks
associated with intellectual property and any related pending or
future litigation and the ultimate outcome of such litigation,
trends in exchange rates and prevailing interest rates, volatile
economic and market conditions, cost containment initiatives and
subsequent changes thereto, and the impact that COVID-19 will have
on us, our customers, suppliers, vendors, and other business
partners, and the financial condition of any one of them, as well
as on our employees and on the global economy as a whole. Any
material effect of COVID-19 on any of the foregoing could also
adversely impact us. This situation is changing rapidly and
additional impacts may arise of which we are not currently aware
and may exacerbate other previously identified risks. The risks and
uncertainties also include the uncertainties discussed or
identified in the public filings with the SEC and the AMF made by
Sanofi, including those listed under “Risk Factors” and “Cautionary
Statement Regarding Forward-Looking Statements” in Sanofi’s annual
report on Form 20-F for the year ended December 31, 2021. Other
than as required by applicable law, Sanofi does not undertake any
obligation to update or revise any forward-looking information or
statements.
Sanofi (BIT:1SAN)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Sanofi (BIT:1SAN)
Historical Stock Chart
Von Apr 2023 bis Apr 2024